SEC warns firms about using non-GAAP numbers
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen’s new drug for migraines shows promise
Thousand Oaks-based Amgen said a drug being developed in collaboration with Novartis showed promising results in providing relief for patients suffering from chronic migraines. The Phase 2 clinical trial met benchmarks for migraine reduction at two levels of dosage and with limited side effects. “Migraine is the sixth-leading cause of disability worldwide. Three to seven Read More →
Amgen subsidiary discovers rare gene that could reduce heart attack risk
An Amgen subsidiary may have found a rare gene that could drastically reduce the risk of heart attacks in the future. DeCode Genetics, an Iceland-based subsidiary of Thousand Oaks biotech giant Amgen, uncovered a rare and unknown genetic variation in some people that could reduce the risk of heart attacks and lower cholesterol. The variant Read More →
NBC locks up Amgen Tour of California coverage through 2019
NBC Sports and AEG Worldwide agreed to a three-year media rights extension of the Amgen Tour of California on May 12. NBC started televising the Tour of California in 2007 during the second year of the weeklong bicycle race. With the extension, NBC Sports Group will retain U.S. media rights on all platforms and will Read More →
Amgen exceeds Wall Street expectations for first quarter earnings
Amgen blew away Wall Street expectations and raised its 2016 guidance when it released first quarter earnings April 28. The Thousand Oaks biotech giant had profits of $2.2 billion, up from $1.91 billion during the same quarter last year. Revenues of $5.53 billion were also up from $5 billion in 2015 and surpassed analyst estimates Read More →
CSUCI may add engineering program in fall
Retiring CSU Channel Islands President Richard Rush said April 21 an engineering program could be launched at the school this fall. Rush said he hopes to make an official announcement in two weeks. He made the surprise announcement at the CSUCI Business and Technology Partnership Leadership Dinner at the Crowne Plaza Hotel in Ventura. Last Read More →
Study results positive for drug Amgen developing to treat osteoporosis
Thousand Oaks-based biotech giant Amgen and Brussels, Belgium-based UCB announced positive results in a Phase 3 trial of romosozumab, an antibody designed to treat osteoporosis. The drug works by inhibiting a protein which results in increased bone formation and decreased bone breakdown. However, the drug is not approved by any regulatory authority for use to Read More →
